Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Scilex Holding Co's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $-308.32 Mil. Scilex Holding Co's Total Assets for the quarter that ended in Jun. 2026 was $253.56 Mil.
Therefore, Scilex Holding Co's Equity to Asset Ratio for the quarter that ended in Jun. 2026 was -1.22.
The historical rank and industry rank for Scilex Holding Co's Equity-to-Asset or its related term are showing as below:
SCLX'
s Equity-to-Asset Range Over the Past 10 Years
Min: -2.97 Med: -1.74 Max: 0.42
Current: -1.22
During the past 7 years, the highest Equity to Asset Ratio of Scilex Holding Co was 0.42. The lowest was -2.97. And the median was -1.74.
SCLX's Equity-to-Asset is ranked worse than 96.12% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 0.6
vs SCLX: -1.22
Scilex Holding Co (NAS:SCLX) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Scilex Holding Co Equity-to-Asset Related Terms
Scilex Holding Co Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Scilex Holding Co's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SCLX vs MIRA, NSRX, MDCX: Equity-to-Asset Comparison
For the Drug Manufacturers - General subindustry, Scilex Holding Co's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scilex Holding Co Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Scilex Holding Co's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Scilex Holding Co's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Scilex Holding Co's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scilex Holding Co (SCLX) has a Equity-to-Asset of -1.22 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Scilex Holding Co and its competitors. According to the industry distribution chart, Scilex Holding Co ranks #967 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 96.1%.
Is Scilex Holding Co's Equity-to-Asset too high?
Scilex Holding Co's current Equity-to-Asset is -1.22. Based on the distribution chart, Scilex Holding Co ranks #967 out of 1006 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Scilex Holding Co has a GF Score™ of 57/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Scilex Holding Co's Equity-to-Asset compare to MIRA and NSRX?
According to the Drug Manufacturers industry distribution chart, Scilex Holding Co ranks #967 out of 1006 companies for Equity-to-Asset. This places Scilex Holding Co in the lower half of its industry. The industry median Equity-to-Asset is 0.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.60, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Scilex Holding Co and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Scilex Holding Co's current Equity-to-Asset is -1.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scilex Holding Co stock overvalued right now?
Based on GuruFocus' analysis, Scilex Holding Co (SCLX) is currently considered Modestly Undervalued. The stock's GF Value™ is $6.35, compared to a current price of $5.44 — trading 14.3% below its estimated fair value. The current Equity-to-Asset is -1.22. Scilex Holding Co's overall GF Score™ is 57/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Scilex Holding Co (SCLX), the current Equity-to-Asset is -1.22 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Scilex Holding Co (SCLX) Overvalued in 2026?
Based on GuruFocus' analysis, Scilex Holding Co stock appears to be undervalued.
The current stock price of $5.44 is trading 14.3% below its estimated GF Value™ of $6.35.
GuruFocus considers Scilex Holding Co to be Modestly Undervalued.
Key valuation signals for SCLX:
Equity-to-Asset: -1.22
GF Value™: $6.35 vs. price of $5.44 (14.3% below fair value)
No single metric tells the full story. See the SCLX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
57GF Score
Get the complete analysis for SCLX
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SCLX has been successfully added to your 
